Linperlisib in Combination With CHOP in Previously Untreated Peripheral T-Cell Lymphoma

This study is testing a new drug called linperlisib combined with standard CHOP chemotherapy as a first treatment for a group of blood cancers called peripheral T-cell lymphomas (PTCL). Researchers want to see if this combination is safe and more effective than standard treatment alone. **You may be eligible if...** - You are 18 or older and have been newly diagnosed with certain types of PTCL (including PTCL-NOS, AITL, enteropathy-related, or hepatosplenic T-cell lymphoma) - You have not received any previous anti-cancer treatment - You have at least one measurable area of cancer visible on scans - Your overall health and organ function are adequate - You do not have hemophagocytic syndrome (a serious immune reaction) **You may NOT be eligible if...** - You have previously taken a PI3K inhibitor drug - Your lymphoma has spread to the brain or spinal fluid - You have active hepatitis B or C infection - You have uncontrolled high blood pressure, serious heart disease, or severe lung disease - You have active HIV infection or a history of organ transplantation - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.